Delta-9-Tetrahydrocannabinol (∆9-THC) and Cannabidiol (CBD) Drug-Drug Interactions
Although prescribing information is often the initial source of information when identifying potential drug-drug interactions, it may only provide a limited number of exemplars or only reference a class of medications without providing any specific medication examples. In the case of medical cannabis and medicinal cannabinoids, this is further complicated by the fact that the increased therapeutic use of marijuana extracts and CBD oil will not have regulatory agency approved prescribing information. The objective of these datasets is to provide a detailed and comprehensive drug-drug interaction list that is aligned with cannabinoid manufacturer prescribing information. The cannabinoid drug-drug interaction information is listed as a PRECIPITANT (cannabinoid) medication that either INHIBITS/INDUCES the metabolism or competes for the same SUBSTRATE target (metabolic enzyme) of an OBJECT (OTHER) medication. In addition to a comprehensive list of drug-drug interactions, we also provide a list of 57 prescription medications displaying a narrow therapeutic index that are potentially impacted by concomitant cannabinoid use (whether through prescription use of cannabinoid medications or therapeutic/recreational use of cannabis and its extracts). This peer reviewed journal article has been published online with the following citation Med Cannabis Cannabinoids (DOI:10.1159/000507998)
|Work Title||Delta-9-Tetrahydrocannabinol (∆9-THC) and Cannabidiol (CBD) Drug-Drug Interactions|
|License||CC BY-NC-ND 4.0 (Attribution-NonCommercial-NoDerivatives)|
|Publication Date||July 12, 2023|
|Deposited||June 08, 2020|
This resource is currently not in any collection.